39.34
-0.15
(-0.38%)
May 24 - Close
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 38.89 - 39.55 |
| 52 week | 36.63 - 42.83 |
| Open | 39.50 |
| Vol / Avg. | 3.20M/3.83M |
| Mkt cap | 33.71B |
| P/E | 17.56 |
| Div/yield | 0.32/2.87 |
| EPS | 2.24 |
| Shares | 857.00M |
| Beta | 0.38 |
| Inst. own | 53% |
Events
Jul 29, 2013
Q2 2013 Teva Pharmaceutical Industries Ltd Earnings Release
May 15, 2013
Teva Pharmaceutical Industries Ltd at Bank of America Merrill Lynch Health Care Conference -
May 8, 2013
Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE -
May 6, 2013
Q1 2013 Teva Pharmaceutical Industries Ltd Earnings Release
May 2, 2013
Q1 2013 Teva Pharmaceutical Industries Ltd Earnings Conference Call -
Apr 23, 2013
Teva Pharmaceutical Industries Ltd at Biotechnology Industry Organization (BIO) International Convention
Mar 14, 2013
Teva Pharmaceutical Industries Ltd at Barclays Healthcare Conference -
Feb 27, 2013
Teva Pharmaceutical Industries Ltd at RBC Capital Markets' Global Healthcare Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 5.60% | 9.63% |
| Operating margin | 6.29% | 10.85% |
| EBITD margin | - | 29.80% |
| Return on average assets | 2.35% | 3.88% |
| Return on average equity | 5.62% | 8.73% |
| Employees | 45,948 | - |
| Carbon Disclosure Rating | - | 69/100 |
Address
5 Basel St., P.O. Box 3190
PETAH TIKVA, 49131
Israel
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)
PETAH TIKVA, 49131
Israel
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Transcripts - SeekingAlpha
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Teva Pharmaceutical Industries Ltd (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva�s active pharmaceutical ingredient (API) business provides vertical integration to Teva�s own pharmaceutical production. The Company�s global operations are conducted from North and Latin America to Europe and Asia. As December 31, 2010, it had direct operations in approximately 60 countries, including 40 finished dosage pharmaceutical manufacturing sites in 19 countries, 28 pharmaceutical research and development (R&D) centers and 21 API manufacturing sites. On October 14, 2011, it acquired Cephalon, Inc.
Officers and directors
| Phillip Frost | Chairman of the Board | |
| Jeremy M. Levin | President, Chief Executive Officer | |
| Moshe Many M.D., Ph.D. | Independent Vice Chairman of the Board | |
| Eyal Desheh | Chief Financial Officer, Group Executive Vice President | |
| Carlo de Notaristefani Ph.D. | President and Chief Executive Officer, Global Operations | |
| Robert Koremans M.D. | President and Chief Executive Officer, Teva Europe Designate | |
| Itzhak Krinsky | Chairman, Teva Japan and Teva South Korea, Head - Business Development Asia-Pacific | |
| Allan Oberman | President and Chief Executive Officer of Teva Americas Generics | |
| Judith Vardi | President and Chief Executive Officer of Teva EMIA and Asia Pacific | |
| Isaac Abravanel | Group Executive Vice President - Human Resources and Chief Integration Officer |